0
     

Report Added
Report already added
Global LKS Treatment Market, By Type (Focal Motor Seizures, Tonic Seizures, Atonic Seizures), By Treatment (Anticonvulsant Drugs, Corticosteroids, Intravenous Immunoglobulins, Surgery, Speech Therapy, Others), By Diagnosis (Electroencephalogram (EEG), MRI, Audiometry, Genetic Testing, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, Competition Forecast and Opportunities, 2017-2027

Global LKS Treatment Market, By Type (Focal Motor Seizures, Tonic Seizures, Atonic Seizures), By Treatment (Anticonvulsant Drugs, Corticosteroids, Intravenous Immunoglobulins, Surgery, Speech Therapy, Others), By Diagnosis (Electroencephalogram (EEG), MRI, Audiometry, Genetic Testing, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, Competition Forecast and Opportunities, 2017-2027

The global LKS treatment market is projected to register growth at a significate rate during the forecast period. The market growth can be attributed to the rising incidences of genetic disorders like LKS syndrome and the increasing demand for effective treatments for speech impairments. Landau-Kleffner syndrome (LKS) is a rare neurogenerative disease often affecting children within the age group of 4 to 7 years. The disease caused by gene mutations can affect the speaking and cognitive abilities of the individual. LKS is more prevalent among males than females. Some of the symptoms of LKS include speech impairment, verbal auditory agnosia, abnormal epileptiform activity, behavioral disturbances, and overt seizures. Rapidly emerging treatment options for managing and treating the symptoms of LKS are supporting the growth of the global LKS treatment market. Surging demand for effective treatment and the growing number of treatment options are further accelerating the growth of the global LKS treatment market. Rising health awareness among the global population and early diagnosis and effective treatment are also contributing to the growth of the global LKS treatment market. The emergence of diseases similar to LKS is creating a demand for pharmaceutical products and therapeutic treatments, which is anticipated to boost the global LKS treatment market growth. Advancing healthcare infrastructure and the development of better pharmaceutical drugs are also supporting the growth of the global LKS treatment market growth.
The global LKS treatment market is segmented on the basis of type, treatment, diagnosis, end user, regional distribution, and competitional landscape. Based on treatment, the market is sub-divided into anticonvulsant drugs, corticosteroids, intravenous immunoglobulins, surgery, speech therapy, and others. Anticonvulsant drugs are anticipated to register the highest growth in the global LKS treatment market during the forecast period due to rapidly increasing advancements in pharmaceutical products and rising incidences of seizures and convulsions among patients suffering from LKS.
Major players operating in the global LKS treatment market are Johnson & Johnson, Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, Abbott Laboratories, Inc., Cipla, Inc., Glenmark Pharmaceuticals Limited, Mankind Pharma Limited, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, etc.

Years considered for this report:
Historical Years: 2017-2020
Base Year: 2021
Estimated Year: 2022E
Forecast Period: 2023F–2027F

Objective of the Study:
•To analyze the historical growth in the market size of global LKS treatment market from 2017 to 2021.
•To estimate and forecast the market size of global LKS treatment market from 2022 to 2027 and growth rate until 2027.
•To classify and forecast global LKS treatment market based on type, treatment, diagnosis, end user, region, and competitive landscape.
•To identify dominant region or segment in the global LKS treatment market.
•To identify drivers and challenges for global LKS treatment market.
•To examine competitive developments such as expansions, new services, mergers & acquisitions, etc., in global LKS treatment market.
•To identify and analyze the profile of leading players operating in global LKS treatment market.
•To identify key sustainable strategies adopted by market players in global LKS treatment market.

Report Scope:
In this report, global LKS treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

•LKS Treatment Market, By Type:
oFocal Motor Seizures
oTonic Seizures
oAtonic Seizures
•LKS Treatment Market, By Treatment:
oAnticonvulsant Drugs
oCorticosteroids
oIntravenous Immunoglobulins
oSurgery
oSpeech Therapy
oOthers
•LKS Treatment Market, By Diagnosis:
oElectroencephalogram (EEG)
oMRI
oAudiometry
oGenetic Testing
oOthers
•LKS Treatment Market, By End User:
oHospitals & Clinics
oAmbulatory Care Centers
oOthers
•LKS Treatment Market, By Region:
oNorth America
United States
Mexico
Canada
oEurope
France
Germany
United Kingdom
Italy
Spain
oAsia-Pacific
China
India
Japan
South Korea
Australia
oMiddle East & Africa
South Africa
Saudi Arabia
UAE
oSouth America
Brazil
Argentina
Colombia

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research was not able to include the companies, which could not be identified due to the limitations of secondary research. TechSci Research analyzed the companies and presence of all major players across the globe.
TechSci Research calculated the market size of global LKS treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these treatments for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:
•LKS treatment service provider companies/partners
•End-Users
•Government bodies such as regulating authorities and policy makers
•Organizations, industry associations, forums and alliances related to global LKS treatment market
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc. besides allowing them in strategizing investments and capitalizing on market opportunities.
Competitive Landscape

Company Profiles:
Detailed analysis of the major companies present in global LKS treatment market.

Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information
•Detailed analysis and profiling of additional market players (up to five).
Table of Contents

1.Service Overview
2.Research Methodology
3.Executive Syummary
4.Impact of COVID-19 on Global LKS Treatment Market
5.Voice of Customer
5.1.Prevalence, By Geography
5.2.Prevalence, By Gender
5.3.Commonly Observed Symptoms
5.4.Preferred Choice of Treatment
6.Global LKS Treatment Market Outlook
6.1.Market Size & Forecast
6.1.1.By Value
6.2.Market Share & Forecast
6.2.1.By Type (Focal Motor Seizures, Tonic Seizures, Atonic Seizures)
6.2.2.By Treatment (Anticonvulsant Drugs, Corticosteroids, Intravenous Immunoglobulins, Surgery, Speech Therapy, Others)
6.2.3.By Diagnosis (Electroencephalogram (EEG), MRI, Audiometry, Genetic Testing, Others)
6.2.4.By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
6.2.5.By Company (2021)
6.2.6.By Region
6.3.Market Map
7.North America LKS Treatment Market Outlook
7.1.Market Size & Forecast
7.1.1.By Value
7.2.Market Share & Forecast
7.2.1.By Type
7.2.2.By Treatment
7.2.3.By Diagnosis
7.2.4.By End User
7.2.5.By Country
7.3.North America: Country Analysis
7.3.1.United States LKS Treatment Market Outlook
7.3.1.1.Market Size & Forecast
7.3.1.1.1.By Value
7.3.1.2.Market Share & Forecast
7.3.1.2.1.By Type
7.3.1.2.2.By Treatment
7.3.1.2.3.By Diagnosis
7.3.1.2.4.By End User
7.3.2.Mexico LKS Treatment Market Outlook
7.3.2.1.Market Size & Forecast
7.3.2.1.1.By Value
7.3.2.2.Market Share & Forecast
7.3.2.2.1.By Type
7.3.2.2.2.By Treatment
7.3.2.2.3.By Diagnosis
7.3.2.2.4.By End User
7.3.3.Canada LKS Treatment Market Outlook
7.3.3.1.Market Size & Forecast
7.3.3.1.1.By Value
7.3.3.2.Market Share & Forecast
7.3.3.2.1.By Type
7.3.3.2.2.By Treatment
7.3.3.2.3.By Diagnosis
7.3.3.2.4.By End User
8.Europe LKS Treatment Market Outlook
8.1.Market Size & Forecast
8.1.1.By Value
8.2.Market Share & Forecast
8.2.1.By Type
8.2.2.By Treatment
8.2.3.By Diagnosis
8.2.4.By End User
8.2.5.By Country
8.3.Europe: Country Analysis
8.3.1.France LKS Treatment Market Outlook
8.3.1.1.Market Size & Forecast
8.3.1.1.1.By Value
8.3.1.2.Market Share & Forecast
8.3.1.2.1.By Type
8.3.1.2.2.By Treatment
8.3.1.2.3.By Diagnosis
8.3.1.2.4.By End User
8.3.2.Germany LKS Treatment Market Outlook
8.3.2.1.Market Size & Forecast
8.3.2.1.1.By Value
8.3.2.2.Market Share & Forecast
8.3.2.2.1.By Type
8.3.2.2.2.By Treatment
8.3.2.2.3.By Diagnosis
8.3.2.2.4.By End User
8.3.3.United Kingdom LKS Treatment Market Outlook
8.3.3.1.Market Size & Forecast
8.3.3.1.1.By Value
8.3.3.2.Market Share & Forecast
8.3.3.2.1.By Type
8.3.3.2.2.By Treatment
8.3.3.2.3.By Diagnosis
8.3.3.2.4.By End User
8.3.4.Italy LKS Treatment Market Outlook
8.3.4.1.Market Size & Forecast
8.3.4.1.1.By Value
8.3.4.2.Market Share & Forecast
8.3.4.2.1.By Type
8.3.4.2.2.By Treatment
8.3.4.2.3.By Diagnosis
8.3.4.2.4.By End User
8.3.5.Spain LKS Treatment Market Outlook
8.3.5.1.Market Size & Forecast
8.3.5.1.1.By Value
8.3.5.2.Market Share & Forecast
8.3.5.2.1.By Type
8.3.5.2.2.By Treatment
8.3.5.2.3.By Diagnosis
8.3.5.2.4.By End User
9.Asia-Pacific LKS Treatment Market Outlook
9.1.Market Size & Forecast
9.1.1.By Value
9.2.Market Share & Forecast
9.2.1.By Type
9.2.2.By Treatment
9.2.3.By Diagnosis
9.2.4.By End User
9.2.5.By Country
9.3.Asia-Pacific: Country Analysis
9.3.1.China LKS Treatment Market Outlook
9.3.1.1.Market Size & Forecast
9.3.1.1.1.By Value
9.3.1.2.Market Share & Forecast
9.3.1.2.1.By Type
9.3.1.2.2.By Treatment
9.3.1.2.3.By Diagnosis
9.3.1.2.4.By End User
9.3.2.India LKS Treatment Market Outlook
9.3.2.1.Market Size & Forecast
9.3.2.1.1.By Value
9.3.2.2.Market Share & Forecast
9.3.2.2.1.By Type
9.3.2.2.2.By Treatment
9.3.2.2.3.By Diagnosis
9.3.2.2.4.By End User
9.3.3.South Korea LKS Treatment Market Outlook
9.3.3.1.Market Size & Forecast
9.3.3.1.1.By Value
9.3.3.2.Market Share & Forecast
9.3.3.2.1.By Type
9.3.3.2.2.By Treatment
9.3.3.2.3.By Diagnosis
9.3.3.2.4.By End User
9.3.4.Japan LKS Treatment Market Outlook
9.3.4.1.Market Size & Forecast
9.3.4.1.1.By Value
9.3.4.2.Market Share & Forecast
9.3.4.2.1.By Type
9.3.4.2.2.By Treatment
9.3.4.2.3.By Diagnosis
9.3.4.2.4.By End User
9.3.5.Australia LKS Treatment Market Outlook
9.3.5.1.Market Size & Forecast
9.3.5.1.1.By Value
9.3.5.2.Market Share & Forecast
9.3.5.2.1.By Type
9.3.5.2.2.By Treatment
9.3.5.2.3.By Diagnosis
9.3.5.2.4.By End User
10.South America LKS Treatment Market Outlook
10.1.Market Size & Forecast
10.1.1.By Value
10.2.Market Share & Forecast
10.2.1.By Type
10.2.2.By Treatment
10.2.3.By Diagnosis
10.2.4.By End User
10.2.5.By Country
10.3.South America: Country Analysis
10.3.1.Brazil LKS Treatment Market Outlook
10.3.1.1.Market Size & Forecast
10.3.1.1.1.By Value
10.3.1.2.Market Share & Forecast
10.3.1.2.1.By Type
10.3.1.2.2.By Treatment
10.3.1.2.3.By Diagnosis
10.3.1.2.4.By End User
10.3.2.Argentina LKS Treatment Market Outlook
10.3.2.1.Market Size & Forecast
10.3.2.1.1.By Value
10.3.2.2.Market Share & Forecast
10.3.2.2.1.By Type
10.3.2.2.2.By Treatment
10.3.2.2.3.By Diagnosis
10.3.2.2.4.By End User
10.3.3.Colombia LKS Treatment Market Outlook
10.3.3.1.Market Size & Forecast
10.3.3.1.1.By Value
10.3.3.2.Market Share & Forecast
10.3.3.2.1.By Type
10.3.3.2.2.By Treatment
10.3.3.2.3.By Diagnosis
10.3.3.2.4.By End User
11.Middle East and Africa LKS Treatment Market Outlook
11.1.Market Size & Forecast
11.1.1.By Value
11.2.Market Share & Forecast
11.2.1.By Type
11.2.2.By Treatment
11.2.3.By Diagnosis
11.2.4.By End User
11.2.5.By Country
11.3.Middle East and Africa: Country Analysis
11.3.1.South Africa LKS Treatment Market Outlook
11.3.1.1.Market Size & Forecast
11.3.1.1.1.By Value
11.3.1.2.Market Share & Forecast
11.3.1.2.1.By Type
11.3.1.2.2.By Treatment
11.3.1.2.3.By Diagnosis
11.3.1.2.4.By End User
11.3.2.Saudi Arabia LKS Treatment Market Outlook
11.3.2.1.Market Size & Forecast
11.3.2.1.1.By Value
11.3.2.2.Market Share & Forecast
11.3.2.2.1.By Type
11.3.2.2.2.By Treatment
11.3.2.2.3.By Diagnosis
11.3.2.2.4.By End User
11.3.3.UAE LKS Treatment Market Outlook
11.3.3.1.Market Size & Forecast
11.3.3.1.1.By Value
11.3.3.2.Market Share & Forecast
11.3.3.2.1.By Type
11.3.3.2.2.By Treatment
11.3.3.2.3.By Diagnosis
11.3.3.2.4.By End User
12.Market Dynamics
12.1.Drivers
12.2.Challenges
13.Market Trends & Developments
14.Competitive Landscape
14.1.Johnson & Johnson
14.2.Novartis AG
14.3.Pfizer, Inc.
14.4.Teva Pharmaceutical Industries Ltd
14.5.Abbott Laboratories, Inc.
14.6.Cipla, Inc.
14.7.Glenmark Pharmaceuticals Limited
14.8.Mankind Pharma Limited
14.9.Novo Nordisk A/S
14.10.Takeda Pharmaceutical Company Limited
15.Strategic Recommendations

Report Title: Global LKS Treatment Market, By Type (Focal Motor Seizures, Tonic Seizures, Atonic Seizures), By Treatment (Anticonvulsant Drugs, Corticosteroids, Intravenous Immunoglobulins, Surgery, Speech Therapy, Others), By Diagnosis (Electroencephalogram (EEG), MRI, Audiometry, Genetic Testing, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, Competition Forecast and Opportunities, 2017-2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW